Close Menu
Farmakopoioi
    Facebook X (Twitter) Instagram
    Farmakopoioi
    • Home
    • Tech
    • News
    • Health
    • Reviews
    • Business
    • Educational
    Farmakopoioi
    Home»Health»Gene Therapy Lets Children Born Deaf Hear for the First Time
    Health

    Gene Therapy Lets Children Born Deaf Hear for the First Time

    Ryder HayesBy Ryder HayesNovember 21, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    A young child having a hearing test.
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Children born profoundly deaf have begun to hear for the first time after a single dose of gene therapy, in what doctors describe as a landmark for the field. The treatment, DB-OTO, was approved by the US Food and Drug Administration in April 2026 under the name Otarmeni, becoming the first gene therapy ever approved for congenital hearing loss. In the CHORD trial, 12 children with profound deafness caused by mutations in the OTOF gene received one infusion of the therapy directly into the inner ear. Hearing improved in 11 of the 12 children, nine reached a level that ended their need for a cochlear implant, and three achieved normal hearing sensitivity within six months. A separate international trial led by Mass Eye and Ear and Fudan University, published in Nature in April 2026, treated 42 people aged from under a year to 32 years and found hearing improved in about 90 percent, with benefits lasting up to two and a half years.

    What the Evidence Shows

    The therapy works by delivering a working copy of the OTOF gene into the inner ear using a harmless virus, restoring production of otoferlin, a protein that inner hair cells need to pass sound signals to the brain. The condition it treats, known as DFNB9, accounts for roughly 2 to 8 percent of hereditary cases of congenital sensorineural hearing loss and affects about 50 babies born each year in the United States. Cochlear implants, the current treatment, bypass the hair cells entirely, so they manage the symptoms without restoring natural hearing. Younger children and those with healthier inner ears responded best, and children treated in both ears scored higher on language and speech tests. About one in ten participants did not respond, and researchers are following patients to confirm the benefit lasts for life. Reporting and analysis from sources such as World Health Organization track the same developments, and specialists following gene therapy for inherited deafness say the direction is now consistent across independent lines of evidence.

    The Wider Context

    The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around gene therapy for inherited deafness is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.

    What Happens Next

    What happens next for gene therapy for inherited deafness depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.

    There is a practical lesson in all of this for readers deciding what to do today. Start with the verified facts, be wary of anyone promising certainty, and prefer reversible steps while the evidence is still developing. Circumstances differ by country, income and personal situation, so general guidance should always be weighed against your own context before you act on it in any significant or lasting way.

    deafness gene therapy hearing
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Ryder Hayes

    Related Posts

    One in Six Common Infections No Longer Respond to Standard Antibiotics, WHO Warns

    November 22, 2026

    Gene Therapy Lets Children Born Deaf Hear for the First Time

    November 21, 2026

    New Blood Pressure Guidance Says Aim Lower, Start Earlier

    November 21, 2026
    Leave A Reply Cancel Reply

    Search
    Recent Posts

    One in Six Common Infections No Longer Respond to Standard Antibiotics, WHO Warns

    November 22, 2026

    Apple’s iOS 27.3 Beta Brings Vertical Tabs and a New Health App

    November 22, 2026

    Gene Therapy Lets Children Born Deaf Hear for the First Time

    November 21, 2026

    Gene Therapy Lets Children Born Deaf Hear for the First Time

    November 21, 2026

    Amazon to Deploy 3,000 Electric Trucks in India

    November 21, 2026

    Phones That Text From Anywhere, Even Without Signal

    November 21, 2026
    About Us

    Farmakopoioi is your trusted source for world, tech, and business coverage. Delivering breaking news, in-depth global business analysis,

    and the latest technology innovation updates, Farmakopoioi provides accurate, reliable, and trustworthy reporting you can depend on in a fast-changing world. #Farmakopoioi

    Popular Posts

    One in Six Common Infections No Longer Respond to Standard Antibiotics, WHO Warns

    November 22, 2026

    Apple’s iOS 27.3 Beta Brings Vertical Tabs and a New Health App

    November 22, 2026
    Contact Us

    If you have any questions or need further information, feel free to reach out to us at

    Email: tech4english@gmail. com
    Phone: +358 44 952 3404

    Address: 4021 Stockert Hollow Road
    Seattle, WA 98109

    Copyright © 2026 | All Rights Reserved | Farmakopoioi
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    • Write For Us
    • Sitemap

    Type above and press Enter to search. Press Esc to cancel.

    WhatsApp us